Cudetaxestat Well-tolerated in Esbriet, Ofev Combos in Phase 1 Trial

Cudetaxestat Well-tolerated in Esbriet, Ofev Combos in Phase 1 Trial

316232

Cudetaxestat Well-tolerated in Esbriet, Ofev Combos in Phase 1 Trial

Cudetaxestat (BLD-0409), an experimental medication for idiopathic pulmonary fibrosis (IPF) from Blade Therapeutics, was well-tolerated among healthy volunteers when given in combination with other IPF treatments — specifically nintedanib and pirfenidone — in a Phase 1 study. “These findings provide confidence in the potential to safely co-administer cudetaxestat on top of the currently approved therapies in patients with uncontrolled IPF,” Wendye Robbins, MD, president and CEO of Blade, said in a press release. Blade is…

You must be logged in to read/download the full post.